top of page



Stay tuned for the first newsletter, coming soon!


A Spiking Fever

Science  |  22 February 2024

Read this article in Science for a recent commentary on surging cases of Lassa fever in West Africa and efforts across the field to tackle this growing health threat.

As CEPI ramps up vaccine research, a new study warns Lassa fever is set to expand its reach across Africa

CEPI  |  11 October 2022

Climate change and other environmental factors could cause Lassa fever to spread to additional regions within Africa, new research predicts. Read the full article here.

IAVI announces first vaccinations at Liberia site in Phase 1 clinical trial of Lassa fever vaccine candidate

IAVI  |  31 August 2022

The trial is designed to evaluate the candidate’s safety, tolerability, and immunogenicity. Read the full press release here.

EDCTP and CEPI funding moves IAVI’s Lassa fever vaccine candidate into advanced clinical development

IAVI  |  14 June 2021

IAVI has received an award of €22.8 million from the European & Developing Countries Clinical Trials Partnership (EDCTP) and the Coalition for Epidemic Preparedness Innovations (CEPI) to conduct a Phase IIb clinical trial of a novel vaccine candidate to prevent Lassa fever disease.. Read the full press release here.

IAVI and the Public Health Agency of Canada Enter into License Agreement for Technology to Enable Lassa Fever Vaccine Development

IAVI  |  14 August 2018

IAVI to apply expertise in viral vector vaccines to Lassa Fever prevention effort. Read the full press release here.

CEPI Partners with IAVI to Advance Lassa Fever Vaccines

IAVI  |  21 May 2018

The Coalition for Epidemic Preparedness Innovations (CEPI) and IAVI announce partnership to develop a Lassa fever vaccine. Read the full press release here.

bottom of page